This clinical consensus statement reviews the use of inotropic support in patients with advanced heart failure. The current guidelines only support use of inotropes in the setting of acute... Show moreThis clinical consensus statement reviews the use of inotropic support in patients with advanced heart failure. The current guidelines only support use of inotropes in the setting of acute decompensated heart failure with evidence of organ malperfusion or shock. However, inotropic support may be reasonable in other patients with advanced heart failure without acute severe decompensation. The clinical evidence supporting use of inotropes in these situations is reviewed. Particularly, patients with persistent congestion, systemic hypoperfusion, or advanced heart failure with need for palliation, and specific situations relevant to implantation of left ventricular assist devices or heart transplantation are discussed. Traditional and novel drugs with inotropic effects are discussed and use of guideline-directed therapy during inotropic support is reviewed. Finally, home inotropic therapy is described, and palliative care and end-of-life aspects are reviewed in relation to management of ongoing inotropic support (including guidance for maintenance and weaning of chronic inotropic therapy support). Show less
This thesis shows the potential utility of imaging biomarkers of the heart, kidneys, and visceral adiposity in the clinical management of cardiorenal syndrome and type 2 diabetes. We explored the... Show moreThis thesis shows the potential utility of imaging biomarkers of the heart, kidneys, and visceral adiposity in the clinical management of cardiorenal syndrome and type 2 diabetes. We explored the methods to quantify visceral fat, and demonstrated the potential clinical implications of a special compartment of visceral fat, renal sinus fat. We summarized the current role of imaging techniques in the clinical management of cardiorenal syndrome, and evaluated the preclinical MRI-derived imaging biomarkers in a group of patients with type 4 cardiorenal syndrome. Our findings could potentially benefit the clinical care for patients with metabolic disorders and/or cardiorenal syndrome. Continuous technical developments in quantitative imaging will increase the potential for applying imaging biomarkers in the management of reno-cardiometabolic diseases, and contribute to achieving the goals of personalized medicine. Show less
